Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587345 | 0.86 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL642956 | 0.85 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL19923130 | 0.83 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2ROR1 | |
| SCHEMBL7068161 | 0.81 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL10106364 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL10330558 | 0.78 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL641310 | 0.77 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL767623 | 0.74 | LARS1 (0.33) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL28599987 | 0.74 | SMN1; SMN2 (0.35) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10106418 | 0.73 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | NPC1 223/4885RAB9A 2841/4885SMN1; SMN2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.